60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

Key Takeaways Explain This Topic AI

Epilepsy is defined by the International League Against Epilepsy (ILAE) as: >=2 unprovoked seizures occurring >24 hours apart, OR 1 unprovoked seizure with a >60% probability of recurrence over the next 10 years (such as a remote structural lesion like stroke or focal epileptiform discharges on EEG).

Second-generation antiseizure medications (ASMs: levetiracetam, lamotrigine, lacosamide) are preferred first-line agents in primary care due to predictable linear pharmacokinetics, oral/IV bioequivalence, absence of hepatic cytochrome P450 enzyme induction, and minimal drug-drug interactions.

Lamotrigine requires slow dose escalation to prevent life-threatening Stevens-Johnson syndrome / TEN; critically, estrogen-containing oral contraceptives and pregnancy double lamotrigine clearance via UGT1A4 induction, cutting serum levels in half and precipitating breakthrough seizures or status epilepticus.

Valproic acid is the broad-spectrum agent of choice for generalized and myoclonic epilepsies, but carries a strict contraindication in women of childbearing potential due to severe teratogenicity (neural tube defects, facial clefts, 7-10 point reduction in offspring IQ); all reproductive-age women taking ASMs require preconception high-dose folic acid (4 mg daily).

Comprehensive post-stroke primary care requires aggressive secondary prevention (high-intensity statin targeting LDL <70 mg/dL, blood pressure <130/80 mmHg, antiplatelets or DOACs for atrial fibrillation), mandatory screening for post-stroke depression (affecting 30% of survivors; treated with SSRIs), cognitive evaluation, and coordinated neurorehabilitation.

Last updated: September 2026

Epilepsy Definition, Seizure Classification & Diagnostic Evaluation

Epilepsy is one of the most prevalent chronic neurological conditions managed in primary care. Under the 2014 International League Against Epilepsy (ILAE) consensus definition, epilepsy is diagnosed when a patient fulfills ANY ONE of the following three criteria:

At least two unprovoked (or reflex) seizures occurring >24 hours apart .

One unprovoked (or reflex) seizure with a probability of further seizures similar to the general recurrence risk (at least 60% ) after two unprovoked seizures, occurring over the next 10 years (e.g., a patient with a single seizure occurring months after an ischemic stroke, or a patient with a single seizure whose brain MRI reveals a structural lesion and whose EEG reveals focal epileptiform discharges).

Diagnosis of a specific, defined epilepsy syndrome (e.g., Juvenile Myoclonic Epilepsy, Lennox-Gastaut syndrome). ILAE 2017 OPERATIONAL SEIZURE CLASSIFICATION

Classification Category Subtypes & Clinical Manifestations Electroclinical Features
═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Focal Onset Seizures • Focal Aware (formerly Simple Partial): consciousness • Originates within neuronal networks

remains fully intact; sensory aura, motor twitching, limited to one cerebral hemisphere.

autonomic symptoms, or psychic phenomena. • Interictal EEG: focal spikes, sharp

Focal Impaired Awareness (formerly Complex Partial): waves, or focal slowing.

consciousness altered/impaired; automatisms (lip-smacking,• May propagate to bilateral tonic-clonic

fumbling, swallowing), post-ictal confusion. seizures (secondary generalization).

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Generalized Onset • Absence: sudden 5-10 second behavioral arrest with • Originates at some point within, and
Seizures unresponsiveness; rapid recovery; typical 3 Hz rapidly engages, bilaterally distributed

generalized spike-and-wave discharges on EEG. cerebral networks simultaneously.

• Generalized Tonic-Clonic (GTC): sudden loss of • Interictal EEG: generalized bilateral

consciousness, tonic extension followed by clonic jerking. synchronous spike-and-wave discharges.

• Myoclonic: shock-like, brief muscle jerks without loss • Broad-spectrum ASMs required; narrow-spectrum

of consciousness; characteristic of Juvenile Myoclonic sodium blockers may aggravate myoclonus/absence!

Epilepsy (JME; morning jerks dropping coffee cup).

• Atonic: sudden loss of postural muscle tone ("drop attack").

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Diagnostic Workup of a First Unprovoked Seizure

History & Collateral Account : Differentiate true seizure from syncope, psychogenic non-epileptic seizures (PNES), and transient ischemic attack (TIA).

High-Yield Differentiator : Lateral border tongue laceration is highly specific (99%) for generalized tonic-clonic seizures (unlike the tip of the tongue in syncope). Prolonged post-ictal confusion (>=15-30 minutes) strongly supports seizure over cardiogenic syncope.

12-Lead Electrocardiogram (ECG) : MANDATORY for every patient presenting with a first-time seizure or transient loss of consciousness to rule out cardiogenic syncope, high-grade AV block, prolonged QTc syndrome, and Brugada syndrome mimicking convulsive syncope.

Laboratory Evaluation : Serum glucose (hypoglycemia), basic metabolic panel (hyponatremia, hypocalcemia), magnesium, liver function tests, complete blood count, and urine toxicology screen.

Structural Neuroimaging : Brain MRI with dedicated epilepsy protocol (including high-resolution coronal T2 and FLAIR thin-slice cuts perpendicular to the long axis of the hippocampus) is the gold standard. It detects subtle structural epileptogenic pathologies: mesial temporal sclerosis (hippocampal sclerosis) , focal cortical dysplasias, cavernous malformations, low-grade tumors (gangliogliomas, DNETs), and ischemic strokes. Emergent non-contrast head CT is reserved for the acute emergency setting to exclude acute intracranial hemorrhage or large mass effect.

Electroencephalography (EEG) : Routine 30-minute awake and sleep-deprived interictal EEG should be obtained within 24 to 48 hours. A normal interictal EEG does NOT rule out epilepsy (up to 50% of initial routine EEGs in patients with proven epilepsy are normal); prolonged ambulatory or inpatient continuous video-EEG monitoring increases diagnostic yield.

Antiseizure Medication (ASM) Selection & Pharmacokinetic Principles

The therapeutic objective of chronic antiseizure medication (ASM) therapy is complete seizure freedom with minimal adverse effects. Monotherapy is the initial goal : approximately 50% of patients achieve seizure freedom on their first ASM monotherapy, and another 15% achieve control with a second single agent. Drug-resistant (refractory) epilepsy is defined as the failure of adequate trials of two tolerated and appropriately chosen ASM schedules (whether monotherapy or combination). SPECTRUM OF ACTIVITY: BROAD-SPECTRUM VS. NARROW-SPECTRUM ASMs

Therapeutic Category Specific Agents Clinical Indications & Critical Prescribing Rules

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Broad-Spectrum ASMs • Levetiracetam • First-line for ALL seizure types: focal onset,
Lamotrigine generalized onset (tonic-clonic, absence, myoclonic),

Valproic Acid / Divalproex and unclassified seizures.
Topiramate • Mandatory choice when seizure onset type is ambiguous.

• Zonisamide

─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Narrow-Spectrum ASMs • Carbamazepine • Indicated ONLY for FOCAL onset seizures.

Phenytoin • DANGER: Narrow-spectrum sodium channel blockers can
Oxcarbazepine PARADOXICALLY WORSEN generalized seizure types

Lacosamide* (particularly absence and myoclonic seizures in JME)!

• Gabapentin / Pregabalin

*Note: Lacosamide is primarily approved for focal onset seizures, though recently approved as adjunctive for generalized tonic-clonic.

Second-Generation & Third-Generation ASMs in Clinical Practice

Second- and third-generation ASMs have largely supplanted first-generation agents as initial therapy in primary care due to predictable linear pharmacokinetics, oral and intravenous bioequivalence, absence of hepatic cytochrome P450 enzyme induction, and superior tolerability profiles. SECOND- AND THIRD-GENERATION ANTISEIZURE MEDICATIONS

Medication & Class Target Maintenance Dosing Metabolism & Elimination Major Adverse Effects & High-Yield Pearls

Levetiracetam (Keppra) 500 to 1500 mg PO BID 66% excreted unchanged in • Rapid titration; 1:1 IV-to-PO bioequivalence.

Synaptic Vesicle 2A (Titrate by 500 mg/day q2w) urine; enzymatic hydrolysis; • No CYP metabolism or protein binding.

(SV2A) Ligand NO hepatic CYP involvement. • NEUROPSYCHIATRIC: Agitation, aggression,

depression, suicidality ("Keppra rage" in 10-15%).

Lamotrigine (Lamictal) 100 to 200 mg PO BID Hepatic glucuronidation via • Broad-spectrum; excellent mood stabilization.

Voltage-Gated Sodium (Slow titration over 6-8 weeks; UGT1A4; NO CYP involvement. • SLOW TITRATION required to prevent SJS/TEN.

Channel Blocker start 25 mg daily x 2 weeks) • CRITICAL: ESTROGEN OCPs DOUBLE CLEARANCE,

slashing levels by 50% (breakthrough seizures)!

Lacosamide (Vimpat) 100 to 200 mg PO BID Renal excretion (40%) and • Linear pharmacokinetics, minimal drug interactions.

Slow Sodium Inactivation (Titrate by 50 mg BID weekly) CYP2C19 demethylation. • Obtain baseline ECG: dose-dependent PR interval

Enhancer prolongation (caution with nodal blockers).

Topiramate (Topamax) 100 to 200 mg PO BID 70% excreted unchanged in • Broad-spectrum; also used for migraine prophylaxis.

Multi-Target: Na+, GABA, (Start 25 mg BID, titrate urine; weak CYP2C19 inhibitor • ADVERSE: Cognitive slowing ("Dopamax"),

AMPA, Carbonic Anhydrase by 50 mg/day weekly) and mild CYP3A4 inducer. weight loss, nephrolithiasis, metabolic acidosis,

acute myopia / angle-closure glaucoma.

1. Levetiracetam (Keppra)

Mechanism : Binds stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, inhibiting presynaptic vesicle exocytosis and reducing action-potential-dependent neurotransmitter release.

Pharmacokinetics : Completely absorbed, linear kinetics, minimal protein binding (<10%), not metabolized by hepatic cytochrome P450 enzymes (cleared primarily by renal elimination; dose-reduce in renal impairment).

Neuropsychiatric Adverse Effects : In 10% to 15% of patients, levetiracetam triggers behavioral irritability, hostility, emotional lability, anxiety, depression, and paranoia (colloquially termed "Keppra rage"). It is relatively contraindicated in patients with active severe psychiatric illness (bipolar disorder, major depression with suicidal ideation). Pyridoxine (vitamin B6, 100 mg daily) can occasionally mitigate mild irritability.

2. Lamotrigine (Lamictal)

Mechanism : Voltage-gated sodium channel blocker and glutamate release inhibitor; broad-spectrum activity with favorable cognitive and mood-stabilizing effects.

Titration & Stevens-Johnson Syndrome (SJS) Risk : Rapid dose escalation substantially increases the risk of severe dermatologic reactions, including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis (TEN). Lamotrigine must be titrated slowly over 6 to 8 weeks (e.g., 25 mg daily for weeks 1-2, 50 mg daily for weeks 3-4, 100 mg daily for week 5, then 200 mg daily).

The Estrogen Oral Contraceptive Interaction (BOARD FAVORITE) : Lamotrigine is cleared predominantly via hepatic glucuronidation mediated by UGT1A4 . Ethinyl estradiol (found in combined oral contraceptive pills, transdermal contraceptive patches, and vaginal rings) induces UGT1A4 glucuronidation, increasing lamotrigine clearance by >100% and cutting serum lamotrigine concentrations by 50% within days . This precipitous drop triggers catastrophic breakthrough seizures and status epilepticus. Conversely, during the placebo "pill-free" week, lamotrigine levels double back up, inducing acute dizziness, ataxia, and diplopia. Management : When starting an estrogen-containing contraceptive, the maintenance lamotrigine dose typically must be doubled; alternatively, recommend a progestin-only intrauterine device (e.g., levonorgestrel IUD), which does not affect glucuronidation.

Valproic Acid Interaction : Valproate strongly inhibits lamotrigine glucuronidation , doubling its elimination half-life and dramatically amplifying the risk of fatal SJS/TEN. If lamotrigine is added to valproate, the starting dose must be halved (25 mg every other day) using a dedicated low-dose titration kit.

First-Generation ASMs: Mechanisms, Toxicities & Drug Interactions

First-generation ASMs have narrow therapeutic indices, exhibit extensive hepatic metabolism, and induce or inhibit cytochrome P450 enzymes, leading to multiple drug interactions and long-term end-organ toxicities. FIRST-GENERATION ANTISEIZURE MEDICATIONS: COMPARISON

Agent & Class Therapeutic Window & Kinetics Enzyme Effects & Interactions Toxicities & Clinical Monitoring

Carbamazepine (Tegretol) 4 to 12 mcg/mL POTENT CYP3A4 INDUCER • AUTOINDUCTION: Induces its own metabolism;

Sodium Channel Blocker Linear clearance; Induces metabolism of OCPs, half-life drops from 36h to 15h after 3-4w.

98% hepatic metabolism. warfarin, statins, and DOACs. • SIADH with hyponatremia (check Na+).

• Aplastic anemia, agranulocytosis (monitor CBC).

• HLA-B*1502 screening in Asian patients (SJS).

Phenytoin (Dilantin) Total: 10 to 20 mcg/mL POTENT INDUCER of CYP3A4, • ZERO-ORDER (SATURATION) PHARMACOKINETICS;

Sodium Channel Blocker Free: 1.0 to 2.0 mcg/mL CYP2C9, CYP2C19, and UGT. small dose increments produce massive toxic jumps.

Nonlinear Michaelis-Menten. Decreases DOACs, warfarin. • Acute toxicity: Nystagmus, ataxia, lethargy.

• Chronic: Gingival hyperplasia, hirsutism,

peripheral neuropathy, cerebellar vermian atrophy.

Valproic Acid / 50 to 100 mcg/mL ENZYME INHIBITOR • Broad-spectrum of choice for generalized/JME.

Divalproex (Depakote) Linear protein binding; Inhibits CYP2C9 and UGT; • Hyperammonemic encephalopathy (normal LFTs!).

GABA Transaminase hepatic glucuronidation doubles lamotrigine levels. • Weight gain, alopecia, pancreatitis, tremor.

Inhibitor & Na+ Blocker and beta-oxidation. • SEVERE TERATOGENICITY: Neural tube defects,

lower IQ; CONTRAINDICATED IN PREGNANCY.

1. Carbamazepine & Genetic Screening

Autoinduction : Carbamazepine induces its own hepatic CYP3A4 metabolism. When initiated, its half-life is approximately 30 to 40 hours, but after 3 to 5 weeks of continuous therapy, autoinduction reduces the elimination half-life to 12 to 18 hours, frequently requiring dosage re-titration.

Hyponatremia : Carbamazepine enhances collecting duct sensitivity to ADH (SIADH-like effect); monitor serum sodium routinely.

HLA-B*1502 Screening : The FDA mandates HLA-B*1502 allele screening prior to initiating carbamazepine in patients of Asian ancestry (Han Chinese, Filipino, Thai, Malaysian, Indian). Carriage of this allele confers an astronomical (>100-fold) relative risk of fatal Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.

2. Phenytoin & Nonlinear Pharmacokinetics

Michaelis-Menten (Zero-Order) Elimination : At low plasma levels, phenytoin clearance is first-order (rate of elimination is proportional to drug concentration). However, within the therapeutic range (10 to 20 mcg/mL), hepatic metabolizing enzymes (CYP2C9 and CYP2C19) become fully saturated . Once saturated, elimination switches to zero-order kinetics (a constant amount of drug is cleared per unit time). Beyond this saturation point, small, seemingly trivial dosage increases (e.g., increasing from 300 mg to 330 mg daily) produce disproportionately massive spikes in serum drug levels, precipitating acute cerebellar toxicity ( horizontal nystagmus, gait ataxia, diplopia, dysarthria, and stupor ).

Protein Binding Adjustments : Phenytoin is 90% bound to serum albumin. In hypoalbuminemia (cirrhosis, nephrotic syndrome, malnutrition, elderly), total measured phenytoin levels are falsely depressed while active unbound free phenytoin remains elevated. The Sheiner-Tozer equation must be used to calculate corrected phenytoin: Corrected Phenytoin = Measured Total Phenytoin 0.2 × Serum Albumin (g/dL) + 0.1 \text{Corrected Phenytoin} = \frac{\text{Measured Total Phenytoin}}{0.2 \times \text{Serum Albumin (g/dL)} + 0.1} Corrected Phenytoin = 0.2 × Serum Albumin (g/dL) + 0.1 Measured Total Phenytoin

3. Valproic Acid / Divalproex Sodium

Broad-Spectrum Efficacy : Valproate remains the most effective ASM for primary generalized tonic-clonic seizures, idiopathic generalized epilepsies, and Juvenile Myoclonic Epilepsy (JME).

Non-Hepatic Encephalopathy : Valproate inhibits the urea cycle enzyme carbamoyl phosphate synthetase I, which can trigger valproate-induced hyperammonemic encephalopathy (VHE) characterized by acute lethargy, confusion, asterixis, and increased seizure frequency in the setting of completely normal transaminases and bilirubin; check serum ammonia immediately in any patient on valproate who develops delirium.

Teratogenicity, Reproductive Health & Pregnancy Management in Epilepsy

Over 90% of women with epilepsy deliver healthy infants. However, uncontrolled maternal convulsive seizures carry significant risks of fetal hypoxia, intracranial hemorrhage, miscarriage, and maternal mortality. The fundamental management rule is to achieve complete seizure control with the lowest effective dose of a single ASM (monotherapy) prior to conception . TERATOGENIC RISK PROFILES OF COMMONLY PRESCRIBED ASMs

Antiseizure Medication Major Congenital Malformation (MCM) Risk Specific Teratogenic Phenotypes & Cognitive Impact

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Valproic Acid HIGHEST RISK (10% to 11%) • Neural tube defects (spina bifida in 1-2%), cleft palate,

(Depakote) Dose-dependent (> 800 mg/day extreme) craniosynostosis, cardiac septal defects.

• NEURODEVELOPMENTAL DEFICITS: Offspring suffer an average

7 to 10 point reduction in IQ and higher autism rates.

• ABSOLUTE CONTRAINDICATION in reproductive-aged females.

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Topiramate MODERATE RISK (4% to 5%) • 5-fold increased risk of oral clefts (cleft lip/palate);

(Topamax) • Fetal growth restriction (small for gestational age [SGA]).

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Carbamazepine & MODERATE RISK (3% to 4%) • Neural tube defects, cardiac anomalies, craniofacial defects

Phenytoin (fetal hydantoin syndrome).

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Levetiracetam & LOWEST RISK (2% to 3%) • Malformation rates EQUIVALENT to baseline unexposed

Lamotrigine SAFEST FIRST-LINE CHOICES IN PREGNANCY general population risk (2% to 3%).

═════════════════════════════════════════════════════════════════════════════════════════════════════════
Preconception Counseling & Gestational Management

High-Dose Folic Acid : All women of childbearing potential taking any antiseizure medication should receive oral folic acid supplementation (4.0 mg daily) starting at least 1 to 3 months prior to conception and continuing through the first trimester to minimize the risk of neural tube defects.

Therapeutic Drug Monitoring During Pregnancy : Plasma clearance of lamotrigine and levetiracetam accelerates dramatically during pregnancy (due to increased renal blood flow and progesterone/estrogen-mediated UGT induction), with serum levels dropping by 50% to 70% as early as the first trimester. Baseline preconception serum levels must be established, and serum ASM levels monitored monthly throughout gestation , with upward dosage titration to prevent gestational breakthrough seizures. Immediately postpartum, clearance normalizes rapidly, requiring prompt dose reduction to pre-pregnancy levels over 7 to 14 days to prevent maternal toxicity.

ASM-Induced Metabolic Bone Disease

Long-term use of hepatic cytochrome P450 enzyme-inducing ASMs (Carbamazepine, Phenytoin, Phenobarbital, Primidone) induces the hepatic microsomal enzyme CYP24A1 , which accelerates the catabolism of 25-hydroxyvitamin D into inactive calcitroic acid metabolites. This produces hypocalcemia, secondary hyperparathyroidism, accelerated bone turnover, osteopenia, osteoporosis, and high fragility fracture rates .

Management : Patients on chronic enzyme-inducing ASMs require baseline and periodic serum 25-hydroxyvitamin D monitoring, routine supplementation with vitamin D3 (1000 to 2000 IU daily) and calcium (1000 to 1200 mg daily), and a screening DEXA scan after 2 to 5 years of continuous therapy.

Comprehensive Post-Stroke Care in Primary Care Practice

Stroke is a leading cause of long-term adult disability. Primary care physicians play a central role in managing chronic secondary prevention, coordinating multidisciplinary neurorehabilitation, and screening for underdiagnosed neuropsychiatric complications. CHRONIC POST-STROKE SECONDARY PREVENTION BUNDLE

Intervention Domain Clinical Target / Guideline Recommendation First-Line Pharmacotherapy / Actions
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Lipid Optimization Target LDL-C < 70 mg/dL (or >= 50% reduction from High-intensity statin: Atorvastatin 80 mg
baseline) for all atherosclerotic ischemic strokes. or Rosuvastatin 40 mg daily; add Ezetimibe

if LDL remains >= 70 mg/dL.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Blood Pressure Control Target BP < 130/80 mmHg after the acute period ACE inhibitor / ARB, Thiazide-like diuretic

to prevent recurrent lacunar and territorial strokes. (Chlorthalidone/Indapamide), or DHP CCB.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Antithrombotic Therapy • Non-Cardioembolic Stroke / TIA: Single antiplatelet • Aspirin 81 mg daily OR Clopidogrel 75 mg daily.

• Short-term DAPT (Aspirin + Clopidogrel x 21 days) • DAPT beyond 21-90 days increases major bleed

for minor stroke (NIHSS <=3) or high-risk TIA (ABCD2 >=4). risk without added ischemic benefit!

• Cardioembolic (Atrial Fibrillation): Full anticoagulation • Direct Oral Anticoagulant (DOAC: Apixaban,

is superior to antiplatelet therapy. Rivaroxaban) preferred over warfarin.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Neuropsychiatric Screen Mandatory screening for POST-STROKE DEPRESSION (PSD; Routine PHQ-9 screening at every visit;

affects ~30% of survivors; impairs functional recovery). First-line: SSRIs (Sertraline, Escitalopram).

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Functional Rehabilitation Multidisciplinary referrals based on deficits: • Physical Therapy (gait, balance, spasticity).

• Occupational Therapy (IADLs, ADLs, home safety).

• Speech Therapy (dysphagia screen, aphasia).

═════════════════════════════════════════════════════════════════════════════════════════════════════════
Post-Stroke Depression (PSD) & Cognitive Impairment

Post-Stroke Depression : Affects approximately one-third of all stroke survivors , with the peak incidence occurring in the first 3 to 6 months post-stroke. Left frontal cortical and basal ganglia infarctions carry particularly high vulnerability. PSD directly impedes participation in physical and occupational rehabilitation, doubles 5-year all-cause mortality, and diminishes quality of life. Clinicians must screen routinely using the Patient Health Questionnaire-9 (PHQ-9) . First-line therapy consists of Selective Serotonin Reuptake Inhibitors (SSRIs) (such as Sertraline 25-100 mg daily or Escitalopram 10-20 mg daily), which promote neuroplastic recovery alongside mood improvement.

Post-Stroke Cognitive Impairment (PSCI) : Up to 50% of stroke survivors experience cognitive deficits within 6 months. Screen at 3 to 6 months using the MoCA , which is highly sensitive for post-stroke subcortical and executive dysfunction.

Driving Safety & Post-Stroke Seizures

Driving Restrictions : Most state motor vehicle departments mandate driving cessation for a minimum of 1 to 3 months following an ischemic stroke or TIA , provided no persistent visual field cut (homonymous hemianopia) or motor deficits remain.

Post-Stroke Seizures : Ischemic stroke is the most common etiology of new-onset epilepsy in older adults (>65 years). A single unprovoked late seizure occurring >7 days post-stroke carries an approximately 70% risk of recurrence , meeting the ILAE definition for epilepsy and mandating initiation of chronic ASM monotherapy (with Levetiracetam or Lamotrigine being preferred choices due to minimal vascular and drug interactions).